ASX:FTT

Factor Therapeutics (FTT) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
425,600 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About Factor Therapeutics

Factor Therapeutics Limited operates as a biotechnology company that focuses on developing and commercializing advanced wound care therapies. The company was formerly known as Tissue Therapies Limited and changed its name to Factor Therapeutics Limited in May 2016. Factor Therapeutics Limited was incorporated in 2002 and is based in Brisbane, Australia.

FTT Stock News Headlines

Anatara Lifesciences Limited (ANR.AX) Chair Transition
See More Headlines
Receive FTT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Factor Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/08/2019
Today
5/14/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1,794.00
Book Value
A$0.03 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Ms. Melanie Farris M.A.I.C.D.
    ACIS) BComn, (AGIA, GradDip, ACG, Company Sec. & Non-Exec. Director

FTT Stock Analysis - Frequently Asked Questions

How were Factor Therapeutics' earnings last quarter?

Factor Therapeutics Limited (ASX:FTT) issued its quarterly earnings data on Thursday, August, 8th. The biotechnology company reported $0.00 earnings per share for the quarter.

This page (ASX:FTT) was last updated on 5/14/2024 by MarketBeat.com Staff

From Our Partners